Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.

摘要: Background/Aim To evaluate long-term outcomes in decompensated HCV-related cirrhotic patients treated with antiviral therapy. Methods Of 129 eligible patients, 66 received peginterferon alfa-2b and ribavirin for 24 weeks, 63 were controls. Survival recurrence of liver failure events after therapy main outcomes. Results Therapy was tolerated by 27 dose reduced 26 toxicity, discontinued 13 intolerance. End-of-therapy sustained virological response (SVR) rates 82.6% 43.5% HCV 2/3 30.2% 7.0% 1/4 patients. During therapy, odds ratios severe infections or deaths due to infection 2.95 (95% C.I. 0.93–9.3) 1.97 0.40–9.51) as compared a follow-up 30 months off-therapy, occurred 52, 33, 3 controls, non-responders, SVR Odds ascites, encephalopathy, oesophageal bleeding significantly decreased Annualized incidence death 2.34, 1.91, 0 per 1000 patient-years, respectively, curves showed early separation from both non-responders controls at approximately 6 months. Conclusions In cirrhotics, clearance is life-saving reduces disease progression.